Liposomes Patents (Class 424/450)
  • Patent number: 11324821
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases and cancers.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: May 10, 2022
    Assignee: ADJUVANCE TECHNOLOGIES, INC.
    Inventors: J Tyler Martin, Jeffrey Gardner
  • Patent number: 11324698
    Abstract: The application disclosure provides a sterically stabilized liposome carrier encapsulating a selected drug for the aerosol delivery of the drug effectual in the treatment of a mammal, a composition containing the sterically stabilized liposome carrier and the selected drug effective for the treatment of airway hypersensitivity and inflammation such as of the lungs of a mammal as an aerosol, and a method of treatment using the composition. The composition disclosed herein provides effective treatment for the longer of a period of time at least twice as long as the selected drug alone or up to at least one week.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: May 10, 2022
    Assignee: VGSK Technologies, Inc.
    Inventors: Kameswari S. Konduri, Sandhya N. Nandedkar, Nejat Duzgunes, Pattisapu Ram Jogi Gangadharam
  • Patent number: 11318131
    Abstract: Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 3, 2022
    Inventors: Bambang Adiwijaya, Jonathan Basil Fitzgerald, Helen Lee
  • Patent number: 11318097
    Abstract: Provided herein are liposomal vesicles comprising at least a first lipid bilayer and a second lipid bilayer, and a plurality of crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein the plurality of crosslinkages comprise boronic ester or thioketal bonds. Also provided are pharmaceutical compositions comprising the liposomal vesicles described herein and a pharmaceutically acceptable excipient. Also provided are methods of making and using the liposomal vesicles. Thus, a method of treating a subject with a disease comprising administering to the subject a pharmaceutical composition comprising the liposomal vesicles is described herein. Methods of making multilamellar liposomal vesicles responsive to reactive oxygen species are also provided.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: May 3, 2022
    Assignee: Verily Life Sciences LLC
    Inventors: Zhan Wang, Stephen Morton
  • Patent number: 11311559
    Abstract: Disclosed herein are methods, compositions and kits for treating a viral infection, for example, COVID-19, MERS and SARS. The disclosed compositions provide for enhanced delivery of the disclosed antiviral agents.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: April 26, 2022
    Assignee: POVIVA CORP.
    Inventors: John Docherty, Christopher Andrew Bunka
  • Patent number: 11306121
    Abstract: The present invention relates to a peptide exhibiting physiological activities and a composition including the peptide. Because the peptide of the present invention exhibits various physiological activities such as muscle relaxation, skin wrinkle improvement, sebum production suppression, and the like, the peptide may be used as an active ingredient in a pharmaceutical composition for muscle relaxation, or cosmetics for improving skin wrinkles, suppressing sebum production, or ameliorating acne.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: April 19, 2022
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim, Eung Ji Lee
  • Patent number: 11304901
    Abstract: The present invention is directed to a liposomal formulation having a lipid ingredient encapsulating fluticasone furoate, and a method for preparing the liposomal formulation. The liposome formulation comprises a lipid and a sterol. The method of preparing the liposomes comprises the steps of (1) mixing fluticasone furoate with lipid ingredients comprising a lipid and a sterol, (2) injecting the mixture into normal saline solution, and (3) ultrafiltering and concentrating the resulting solution. This preparation method can produce a liposome formulation having desirable properties and compositions, for example, the ratio of the lipid ingredient, the drug to lipid ratio, and the pH value, which is suitable for nebulization inhalation.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 19, 2022
    Assignee: ANOVENT PHARMACEUTICAL (U.S.), LLC
    Inventors: Cai Gu Huang, Hailong Zhang, Abid Hussain
  • Patent number: 11297835
    Abstract: The present invention relates to compositions of perillic acid compounds, therapeutic and non-therapeutic uses of the compounds and compositions as well as a method of preparing the composition.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: April 12, 2022
    Assignee: BRAIN BIOTECH AG
    Inventors: Jessica Rehdorf, Alice Kleber
  • Patent number: 11298419
    Abstract: The present invention provides novel antigens of an allergy to a quail egg, methods and kits for diagnosing an allergy to a quail egg, pharmaceutical compositions comprising such an antigen, and quail eggs or processed products of quail egg which are devoid of such an antigen.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: April 12, 2022
    Assignee: HOYU CO., LTD.
    Inventors: Kayoko Matsunaga, Akiko Yagami, Yasuto Kondo, Kazuhiro Hara, Masashi Nakamura, Yuji Aoki
  • Patent number: 11298314
    Abstract: The present invention relates to a composition comprising glycocholic acid or taurocholic acid and phosphatidylcholine at a particular mixing ratio for reducing localized fat without side effects such as a pain, edema, necrosis of muscle cells, fibroblasts and vascular endothelial cells other than adipocytes, anesthesia of administration sites, extensive swelling, erythema, induration, paresthesia, nodule, pruritus, burning sensation, nerve injury, and dysphagia, and a method for preparing the same. The inventor has found that the effect of PPC injectable composition on fat reduction may be reduced or enhanced during its subcutaneous administration, depending on the types of solubilizing agents, especially the types of bile acids, which are combined so as to prepare a safe and stable PPC injection using insoluble PPC.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: April 12, 2022
    Assignee: AMI PHARM CO., LTD.
    Inventor: Ki Taek Lee
  • Patent number: 11291635
    Abstract: Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: April 5, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICAL SA
    Inventors: Andrew Geall, Christian Mandi, Derek O'Hagan, Manmohan Singh
  • Patent number: 11291644
    Abstract: The described invention provides methods for treating pulmonary cancer in a subject, by administering to the subject by inhalation a composition of inhalational lipid cisplatin (ILC) comprising a lipid-complexed cisplatin.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: April 5, 2022
    Assignee: ELEISON PHARMACEUTICALS, LLC
    Inventors: Forrest H. Anthony, Matthew M. Parris, Edwin J. Thomas, Guangtao Zhang
  • Patent number: 11285106
    Abstract: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: March 29, 2022
    Assignee: Northwestern University
    Inventors: C. Shad Thaxton, Chad A. Mirkin, Kaylin M. McMahon, Sushant Tripathy, Raja Kannan Mutharasan, David M. Leander, Andrea Luthi
  • Patent number: 11285222
    Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: March 29, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
  • Patent number: 11286345
    Abstract: Disclosed herein are poly(hydroxylalkyleneimine disulfide)polymers, which have both desirable transfection properties and reduced toxicity.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: March 29, 2022
    Assignee: Thermo Fisher Scientific Baltics UAB
    Inventors: Sarunas Zigmantas, Lolita Zaliauskiene, Ricardas Makuska, Alma Bockuviene, Ausvydas Vareikis
  • Patent number: 11278616
    Abstract: The present invention provides an immunity induction-promoting composition which has a track record of use as a medicine or medicinal additive and is capable of safely and effectively inducing cellular immune response, and a vaccine pharmaceutical composition containing the immunity induction-promoting composition. The present invention relates to an immunity induction-promoting composition containing an immunity induction promoter whose active ingredient is an antimicrobial drug.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: March 22, 2022
    Assignee: NITTO DENKO CORPORATION
    Inventors: Kyohei Matsushita, Daisuke Asari, Takuya Shishido, Mitsuhiko Hori
  • Patent number: 11278592
    Abstract: A method of treating a subject having a cancer comprising administering a tumor suppressor therapy, such as a TUSC2 therapy, in conjunction with an immune checkpoint inhibitor. Kits and reagents for use in cancer therapy are also provided.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: March 22, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jack A. Roth, Lin Ji
  • Patent number: 11278512
    Abstract: Presented herein are compositions comprising L-serine, or a precursor, derivative or conjugate thereof, and a non-toxic metal, such as zinc. Compositions disclosed herein can be used for the prevention and treatment of neurodegenerative diseases, or related symptoms thereof.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 22, 2022
    Assignee: BRAIN CHEMISTRY LABS
    Inventors: Paul Alan Cox, Sandra Anne Banack, James S. Metcalf, Rachael Dunlop
  • Patent number: 11275087
    Abstract: The present invention relates to a test support method which is a means for predicting whether or not pathological complete response (pCR) will be attained when a preoperative chemotherapy with an anticancer drug is performed, the method using a sample (breast cancer tissue section) collected from a breast cancer patient to be subjected to the preoperative chemotherapy. The test support method includes: [1] the step of acquiring a fluorescence image of a breast cancer tissue section, which fluorescence image shows bright spots of fluorescent nanoparticles labeling one or more kinds of breast cancer-related proteins; [2] the step of acquiring at least one index relating to the expression level(s) of the breast cancer-related protein(s) on the basis of the bright spots of the fluorescence image; and [3] the step of acquiring information for predicting pCR by performing an analysis using the above-described at least one index.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: March 15, 2022
    Assignee: KONICA MINOLTA, INC.
    Inventors: Hideki Gouda, Masaru Takahashi, Kensaku Takanashi, Hisatake Okada, Yuichi Ozaki, Yuka Yoshihara, Yasushi Nakano, Kohsuke Gonda, Noriaki Ohuchi, Mika Watanabe, Norikazu Masuda, Masakazu Toi, Hiroshi Tada, Minoru Miyashita
  • Patent number: 11274194
    Abstract: Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: March 15, 2022
    Assignee: MEDCURA, INC
    Inventor: Matthew Dowling
  • Patent number: 11273216
    Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: March 15, 2022
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • Patent number: 11266600
    Abstract: The invention relates to an emulsion for the topical treatment of dermal infections and mucosal infections, in particular of urogenital infectious diseases, characterized in that an antimicrobial agent and an anti-adhesive agent, preferably an NSAID, are used in combination.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: March 8, 2022
    Assignee: ProFem GmbH
    Inventors: Marion Noe, Christian R. Noe
  • Patent number: 11266604
    Abstract: Non-vesicular nanoparticles which have antibacterial activity and are made from a C8-C28 fatty acid or a derivative thereof, a surfactant and an optional lipid.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: March 8, 2022
    Assignee: ALAYA (SHANGHAI) BIOSCIENCE CO., LTD.
    Inventors: Yun Tan, Gang Wang
  • Patent number: 11266822
    Abstract: An object of the present invention is to provide a microneedle array which is capable of suppressing aggregation of liposomes in a case where a water-soluble polymer is mixed with liposomes during production of the microneedle array and is capable of localizing a drug at a tip of a needle. According to the present invention, provided is a microneedle array including: a sheet; and a plurality of needles which are present on an upper surface of the sheet, in which each needle contains a water-soluble polymer, a drug, a liposome, and a salt, a zeta potential of the liposome is ?10 mV or less, the zeta potential is a zeta potential of a liquid obtained by diluting the liposome to 0.1 mg/mL with 10 mmol/L of a phosphoric acid aqueous solution having a pH of 7, and a content of the salt in a portion of each needle which contains the liposome is 2.5 mmol/g or less.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: March 8, 2022
    Assignee: FUJIFILM Corporation
    Inventor: Toshio Shimada
  • Patent number: 11260033
    Abstract: Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of CBD to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: March 1, 2022
    Assignee: DISRUPTION LABS INC.
    Inventors: Brian R. Sloat, Michael A. Sandoval, Tyler B. West
  • Patent number: 11260132
    Abstract: The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: March 1, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Marsha A. Moses, Peng Guo, Jiang Yang, Debra Auguste, Daxing Liu
  • Patent number: 11253462
    Abstract: The invention relates to a composition comprising: (i) a trialkylsiloxysilylcarbamoyl pullulan compound, (ii) a polymethyl methacrylate polymer, (iii) a mattifying substance, and (iv) at least one volatile hydrocarbon oil. The invention is also targeted at the use of such a composition for making up and/or caring for keratinous substances, the skin and the lips, and more particularly in mascaras, foundations and lipsticks.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: February 22, 2022
    Assignee: LVMH RECHERCHE
    Inventors: Yohann Bichon, Caroline Koussouros
  • Patent number: 11253506
    Abstract: The present invention includes compounds, compositions and methods for treating and/or preventing chlorine inhalation toxicity and/or injury in a subject subjected to chlorine inhalation.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: February 22, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Livia A. Veress
  • Patent number: 11253603
    Abstract: Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: February 22, 2022
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Michael Chorny, Ivan Alferiev, Garrett M. Brodeur
  • Patent number: 11246877
    Abstract: Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 15, 2022
    Assignee: The University of Chicago
    Inventors: Wenbin Lin, Xiaopin Duan, Christina Chan, Wenbo Han
  • Patent number: 11246831
    Abstract: Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: February 15, 2022
    Assignee: PARTICLE SCIENCES, INC.
    Inventors: Andrew Loxley, Mark Mitchnick, David Fairhurst, Christy Ann Eatmon
  • Patent number: 11234992
    Abstract: The disclosure provides for therapies and methods to treat atherosclerosis and/or hyperlipidemia, and complications resulting therefrom, with compositions that comprise therapeutically effective amounts of one or more human milk oligosaccharides.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 1, 2022
    Assignee: The Regents of the University of California
    Inventors: Philip Gordts, Ariane Pessentheiner, Lars Bode
  • Patent number: 11235053
    Abstract: The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: February 1, 2022
    Assignee: EMERGEX VACCINES HOLDING LIMITED
    Inventor: Ramila Philip
  • Patent number: 11224655
    Abstract: This invention related to manufactured microbubbles, as well as methods of using manufactured microbubbles, for example, in medicinal applications. The invention pertains to the physical structure and materials of the microbubbles, as well as to methods for manufacturing microbubbles, methods for targeting microbubbles for specific medicinal applications, and methods for delivering microbubbles in medical treatment.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: January 18, 2022
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Robert H. Grubbs, Marshall Leedy Stoller, Hoyong Chung, Alissa M. Fitzgerald, Thomas W. Kenny, Renee M. Thomas
  • Patent number: 11219591
    Abstract: The present invention relates to an ear-cleansing agent for companion animals and a method of manufacturing the same. More particularly, the present invention relates to an ear-cleansing agent for companion animals, which includes distilled Chamaecyparis obtusa water extracted from Chamaecyparis obtusa trees so as to enable antibacterial action, deodorization, and exfoliation and which does not include a surfactant so that the skin is not irritated even when the ear-cleansing agent is not washed away using water, and a method of manufacturing the same.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 11, 2022
    Assignee: KOONA ENT CO., LTD.
    Inventor: Jun Bae Kang
  • Patent number: 11217805
    Abstract: This invention relates to a point of use Hydrogen production unit for use with a Hydrogen fuel cell. The unit uses energy compression to produce a high energy pulse which reacts with the plasma of a gas filled flashlamp to produce a very high pulse of power which is discharged into the water via the surface of the flashlamp to activate the photocatalyst's surface and water interface to produce Hydrogen gas in a water tank or vessel having a gas filled flashlamp or a side emitting fiber optic array. The Hydrogen gas is fed to a storage container and thence to a fuel cell whom it is converted into power to drive vehicles, ships, airplanes, underwater vehicles, boats, etc.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 4, 2022
    Inventor: Richard W. Fahs, II
  • Patent number: 11213604
    Abstract: The invention relates to a composition for dressing cutaneous lesions, in particular cutaneous leishmanial lesions or cutaneous lesions due to actinic keratosis, comprising, based on the total weight of the composition:—10.0 weight percent to 35 weight percent of a one or more diols, selected from the group comprising 1,2-propylene glycol, 1,2-pentanediol, 1,3-butanediol and 2,2?-[Ethane-1,2-diylbis(oxy)]di(ethan-1-ol),—2.0 weight percent to 20 weight percent of at least one first film-forming agent, selected from one or more of a cellulose derivative, hemicellulose, a hemicellulose derivative, chitosan, a chitosan derivative, or oligoglucosamines,—0.2 to 25.0 weight percent of at least one elastic second film-forming agent, selected from one or more thickening agents,—0.2 to 25.0 weight percent of one or more polymeric surfactants,—0.005 to 0.5 weight percent chlorate-free chlorite,—water adding up to 100.0 weight percent.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 4, 2022
    Inventors: Kurt-Wilhelm Stahl, Kurt Bauer
  • Patent number: 11213503
    Abstract: The invention concerns antimicrobial compositions comprising free fatty acids emulsified with membrane lipids or hydrolysed derivatives thereof, and pharmaceutical formulations comprising same. The compositions can be used in the treatment of prophylaxis of microbial infections. They can also regulate the rate of blood clotting rendering them suitable for incorporation in catheter locking solutions and for use in wound care.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: January 4, 2022
    Assignee: WESTGATE BIOMEDICAL LTD.
    Inventor: Michael Anthony Folan
  • Patent number: 11213486
    Abstract: The drug-containing fat emulsion of the present invention, which comprises at least a slightly water soluble drug, an oil or fat, an emulsifier, and water as components, is characterized by having a content of the oil or fat of 2 to 120 mg/mL (excluding 2 mg/mL), having a weight ratio of the drug to the oil or fat (drug/(oil or fat)) of 0.001 to 20 (provided that the total content of the drug and the oil or fat is at most 125 mg/mL), having a content of lecithin as the emulsifier of 50 to 200 mg/mL (in which 50% by weight or less of the used lecithin is optionally replaced by an emulsifier other than lecithin), and having a turbidity of 0.5 or lower.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 4, 2022
    Assignee: TECHNO GUARD CO. LTD.
    Inventor: Kiichiro Nabeta
  • Patent number: 11213487
    Abstract: A method for manufacturing a negatively charged supported lipid bilayer. The method comprises the steps of preparing a formulation comprising at least three lipids (1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), cholesterol and at least one lipid different from DOPS and cholesterol) dissolved in a first solvent, of evaporating the first solvent, of adding an aqueous formulation of mesoporous silica nanoparticles, of performing an ultra-sonication and of performing a centrifugation. The method is remarkable in that the number of equivalents of cholesterol relative to one equivalent of DOPS is comprised between 2.30 and 2.70. Additionally, negatively charged supported lipid bilayer on a mesoporous silica nanoparticle comprising cholesterol, 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) and at least one lipid different from DOPS and cholesterol.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 4, 2022
    Assignee: LUXEMBOURG INSTITUTE OF SCIENCE & TECHNOLOGY (LIST)
    Inventors: Gaelle Corne, Damien Lenoble, Jean-Sebastien Thomann
  • Patent number: 11207428
    Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 28, 2021
    Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.
    Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe Gray
  • Patent number: 11208405
    Abstract: The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents;
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: December 28, 2021
    Assignee: SENTINEL ONCOLOGY LIMITED
    Inventors: Robert George Boyle, David Winter Walker, Richard Justin Boyce
  • Patent number: 11207414
    Abstract: The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: December 28, 2021
    Assignee: Graphium Biosciences, Inc.
    Inventors: Brandon J. Zipp, Janee M. Hardman, Robert T. Brooke
  • Patent number: 11208468
    Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 28, 2021
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Rajasekharan Somasundaram, Meenhard Herlyn, Dorothee Herlyn
  • Patent number: 11202860
    Abstract: A drug delivery system includes a substrate, an integrated sensor disposed on the substrate, a drug delivery element disposed on the substrate, and a control unit coupled to the integrated sensor and the drug delivery element. The integrated sensor includes first and second electrodes disposed on a first surface of the substrate. The drug delivery element includes a reservoir disposed on the first surface of the substrate, a thermally active polymer enclosing the reservoir, and a heating coil disposed over the thermally active polymer. The control unit is configured to measure a biological parameter by measuring a voltage difference between the first and second electrodes of the integrated sensor, and to apply a trigger signal to the heating coil of the drug delivery element responsive to the measured biological parameter indicating a designated condition to heat up the thermally active polymer to selectively release a drug from the reservoir.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: December 21, 2021
    Assignee: International Business Machines Corporation
    Inventors: Qing Cao, Shu-Jen Han, Jianshi Tang, Bharat Kumar
  • Patent number: 11202820
    Abstract: The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions. In the preferred embodiment, the protein nanocage is composed of Bacillus stearothermophilus E2 protein of pyruvate dehydrogenase multi-enzyme complex (E2), with a skin penetrating and cell permeating SPACE moiety, and a melanocyte-targeting moiety of alpha melanocyte stimulating hormone.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: December 21, 2021
    Assignees: NANYANG TECHNOLOGICAL UNIVERSITY, NATIONAL SKIN CENTER (S) PTE LTD
    Inventors: Sierin Lim, Sathyamoorthy Bhaskar, Steven Thng, Ambili Kuniyil, Sarker Mridul
  • Patent number: 11191774
    Abstract: Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: December 7, 2021
    Assignee: The Regents of the University of California
    Inventors: Samir Mitragotri, Marta Broto, Kathryn M. Camacho, Stefano Menegatti
  • Patent number: 11191288
    Abstract: The present invention relates to the field of reduction of methane emission in ruminants. Particularly, it relates to the use of a feed composition or a feed additive comprising at least one fatty acid containing at least 5 carbon atoms and at least one organic molecule substituted at any position with at least one nitrooxy group, for reducing the production of methane emanating from the digestive activities of ruminants, and/or to improve the ruminant performance.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: December 7, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Stephane Duval, Maik Kindermann
  • Patent number: 11191848
    Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: December 7, 2021
    Assignee: Vascular Biogenics Ltd.
    Inventors: Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
  • Patent number: 11185096
    Abstract: A consumable composition may include naringenin at concentrations suitable to improve certain characteristics of the composition. Naringenin may, for example, be added to a composition or included in a sweetening composition that may be added therein to adjust sweetness attributes. For example, beverages that include one or more steviol glycosides may typically be deficient in upfront sweetness, and naringenin may be added therein to improve the temporal profile of sweetness delivery.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: November 30, 2021
    Assignee: DR PEPPER/SEVEN UP, INC.
    Inventors: Stacey K. Walton, Gino E. Olcese